Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vaxcyte (PCVX) Shares Outstanding (Weighted Average) (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Shares Outstanding (Weighted Average) data on record, last reported at $139.5 million in Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 2.81% to $139.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $139.5 million, a 2.81% increase, with the full-year FY2025 number at $136.1 million, up 11.55% from a year prior.
  • Shares Outstanding (Weighted Average) reached $139.5 million in Q1 2026 per PCVX's latest filing, up from $136.1 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for PCVX hit a ceiling of $139.5 million in Q1 2026 and a floor of $57.5 million in Q1 2022.
  • A 5-year average of $104.6 million and a median of $111.7 million in 2024 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 68.98% in 2023, then grew 2.81% in 2026.
  • Tracing PCVX's Shares Outstanding (Weighted Average) over 5 years: stood at $64.9 million in 2022, then soared by 49.75% to $97.2 million in 2023, then rose by 25.57% to $122.0 million in 2024, then rose by 11.55% to $136.1 million in 2025, then grew by 2.51% to $139.5 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for PCVX at $139.5 million in Q1 2026, $136.1 million in Q4 2025, and $136.0 million in Q3 2025.